Lalitagauri M. Deshpande
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lalitagauri M. Deshpande has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Mariana Castanheira
Element Materials Technology (JMI Laboratories)
13 shared publications - Helio Silva Sader
Element Materials Technology (JMI Laboratories)
4 shared publications - Timothy B. Doyle
JMI Laboratories , North Liberty, Iowa
4 shared publications Cecilia G. Carvalhaes
Element Iowa City (JMI Laboratories), North Liberty, Iowa, USA
2 shared publications- Jill Lindley
JMI Laboratories, North Liberty, Iowa
2 shared publications - John H. Kimbrough
Element Materials Technology (JMI Laboratories)
2 shared publications
Latest Publications
- Open Access
- 2 July 2026
- Published by Oxford University Press (OUP) in JAC-Antimicrobial Resistance
- Vol. 8 (4)
Occurrence of β-lactamases among Enterobacterales isolates from 22 US hospitals in a 10-year period: report from the International Network for Optimal Resistance Monitoring (INFORM) programme
Background: We analysed 10 years of data from the INFORM programme, which surveys β-lactamases and the activity of ceftazidime-avibactam in US hospitals. Methods: A total of 33 701 Enterobacterales isolates consecutively collected in 22 US hospitals during 2013–22 were susceptibility tested. Escherichia coli and Klebsiella pneumoniae displaying MICs ≥ 2 mg/L for two of ceftriaxone, ceftazidime, cefepime or aztreonam; or carbapenem-resistant Enterobacterales (CRE) were evaluated for the presence of β-lactamase genes using microarray/PCR (2013–15) or whole genome sequencing (2016–22). Results: ESBLs were detected among 2325/2681 (15.5% of 14 923 overall non-CRE isolates) E. coli and 874/954 (13.3% of 6572) K. pneumoniae. The most common ESBL in both groups was CTX-M-15–like (10.4% of E. coli and 10.7% of K. pneumoniae isolates). A decline in E. coli producing CTX-M-15–like was noted in 2022 (12.6% in 2021 and 8.3% in 2022), and SHV ESBLs had a steady decline among K. pneumoniae since 2015. CRE isolates declined steadily from 1.6% in 2013 to 0.8% in 2022. Carbapenemase-positive isolates also declined from 1.3% to 0.5%, with a decline in KPC producers but an increase in isolates producing NDM; NDM producers were initially detected in 2015 and ranged from 1 to 7 isolates collected in the last 5 study years. Ceftazidime-avibactam and the carbapenems are the most active agents against β-lactamase–producing isolates. Conclusions: Changes in β-lactamase–producing isolates and their susceptibility profiles should be closely monitored at a local and global level since these shifts impact patient treatment, but longitudinal data such as this information is scarce.
- 2 July 2026
- Published by Oxford University Press (OUP) in JAC-Antimicrobial Resistance
- Vol. 8 (4)
Open AccessOccurrence of β-lactamases among Enterobacterales isolates from 22 US hospitals in a 10-year period: report from the International Network for Optimal Resistance Monitoring (INFORM) programme
Background: We analysed 10 years of data from the INFORM programme, which surveys β-lactamases and the activity of ceftazidime-avibactam in US hospitals. Methods: A total of 33 701 Enterobacterales isolates consecutively collected in 22 US hospitals during 2013–22 were susceptibility tested. Escherichia coli and Klebsiella pneumoniae displaying MICs ≥ 2 mg/L for two of ceftriaxone, ceftazidime, cefepime or aztreonam; or carbapenem-resistant Enterobacterales (CRE) were evaluated for the presence of β-lactamase genes using microarray/PCR (2013–15) or whole genome sequencing (2016–22). Results: ESBLs were detected among 2325/2681 (15.5% of 14 923 overall non-CRE isolates) E. coli and 874/954 (13.3% of 6572) K. pneumoniae. The most common ESBL in both groups was CTX-M-15–like (10.4% of E. coli and 10.7% of K. pneumoniae isolates). A decline in E. coli producing CTX-M-15–like was noted in 2022 (12.6% in 2021 and 8.3% in 2022), and SHV ESBLs had a steady decline among K. pneumoniae since 2015. CRE isolates declined steadily from 1.6% in 2013 to 0.8% in 2022. Carbapenemase-positive isolates also declined from 1.3% to 0.5%, with a decline in KPC producers but an increase in isolates producing NDM; NDM producers were initially detected in 2015 and ranged from 1 to 7 isolates collected in the last 5 study years. Ceftazidime-avibactam and the carbapenems are the most active agents against β-lactamase–producing isolates. Conclusions: Changes in β-lactamase–producing isolates and their susceptibility profiles should be closely monitored at a local and global level since these shifts impact patient treatment, but longitudinal data such as this information is scarce.
- Open Access
- 9 June 2025
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 44, 103-110
Activity of aztreonam-avibactam and ceftazidime-avibactam against β-lactamase-producing enterobacterales Isolates from United States hospitals
- 9 June 2025
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 44, 103-110
Open AccessActivity of aztreonam-avibactam and ceftazidime-avibactam against β-lactamase-producing enterobacterales Isolates from United States hospitals
- Open Access
- 28 February 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (3) , ofae702
Activity of Rezafungin Against Echinocandin Non–wild type Candida glabrata Clinical Isolates From a Global Surveillance Program
Among 1463 Candida glabrata isolates collected in 39 US hospitals, 91 (6.2%) were non–wild type to ≥1 echinocandins (ECH-NWT) when tested by the Clinical and Laboratory Standards Institute (CLSI) reference broth microdilution method and interpretative criteria. Rezafungin breakpoints established by the US Food and Drug Administration (FDA) were also applied. ECH-NWT isolates were noted in all US census divisions, and 71 (79.0% of ECH-NWT) carried FKS hot spot (HS) alterations. S663P in FKS2 HS1 (31 isolates) was the most common alteration, followed by substitutions/deletions in position F659 in FKS2 HS1 (14 isolates) and S629P in FKS1 HS1 (9 isolates). Six isolates had substitutions in the HSs of FKS1 and FKS2, and 8 other alterations were noted in the 11 remaining isolates. When CLSI/FDA breakpoints were applied, rezafungin was active against 97.5%/95.3% and 59.3%/23.9% of the overall C glabrata and ECH-NWT isolates, respectively. Anidulafungin, caspofungin, and micafungin inhibited 93.9%/13.2%, 95.7%/33.0%, and 95.6%/29.7% of the overall C glabrata/ECH-NWT isolates. Isolates that did not harbor FKS HS substitutions were more susceptible to echinocandins when compared with isolates with substitutions (47.4%–100% and 4.2%–49.3%; lowest for anidulafungin and highest for rezafungin per the CLSI breakpoint). Isolates harboring the FKS2 HS1 S663P alterations were more resistant to echinocandins—3.2% susceptible (anidulafungin) to 35.5% (rezafungin CLSI breakpoint)—when compared with other single alterations. Rezafungin dosing and pharmacokinetic/pharmacodynamic characteristics allow for coverage of higher minimum inhibitory concentration values, making this agent an attractive option for some isolates that carry FKS alterations and still demonstrate rezafungin-susceptible minimum inhibitory concentration values.
- 28 February 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (3) , ofae702
Open AccessActivity of Rezafungin Against Echinocandin Non–wild type Candida glabrata Clinical Isolates From a Global Surveillance Program
Among 1463 Candida glabrata isolates collected in 39 US hospitals, 91 (6.2%) were non–wild type to ≥1 echinocandins (ECH-NWT) when tested by the Clinical and Laboratory Standards Institute (CLSI) reference broth microdilution method and interpretative criteria. Rezafungin breakpoints established by the US Food and Drug Administration (FDA) were also applied. ECH-NWT isolates were noted in all US census divisions, and 71 (79.0% of ECH-NWT) carried FKS hot spot (HS) alterations. S663P in FKS2 HS1 (31 isolates) was the most common alteration, followed by substitutions/deletions in position F659 in FKS2 HS1 (14 isolates) and S629P in FKS1 HS1 (9 isolates). Six isolates had substitutions in the HSs of FKS1 and FKS2, and 8 other alterations were noted in the 11 remaining isolates. When CLSI/FDA breakpoints were applied, rezafungin was active against 97.5%/95.3% and 59.3%/23.9% of the overall C glabrata and ECH-NWT isolates, respectively. Anidulafungin, caspofungin, and micafungin inhibited 93.9%/13.2%, 95.7%/33.0%, and 95.6%/29.7% of the overall C glabrata/ECH-NWT isolates. Isolates that did not harbor FKS HS substitutions were more susceptible to echinocandins when compared with isolates with substitutions (47.4%–100% and 4.2%–49.3%; lowest for anidulafungin and highest for rezafungin per the CLSI breakpoint). Isolates harboring the FKS2 HS1 S663P alterations were more resistant to echinocandins—3.2% susceptible (anidulafungin) to 35.5% (rezafungin CLSI breakpoint)—when compared with other single alterations. Rezafungin dosing and pharmacokinetic/pharmacodynamic characteristics allow for coverage of higher minimum inhibitory concentration values, making this agent an attractive option for some isolates that carry FKS alterations and still demonstrate rezafungin-susceptible minimum inhibitory concentration values.
- Open Access
- 19 February 2025
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 63 (2) , e0112924
Anidulafungin is a useful surrogate marker for predicting in vitro susceptibility to rezafungin among five Candida species using CLSI methods and interpretive criteria
This study addresses the use of other echinocandins as surrogate markers to predict the susceptibility of rezafungin against the six most common Candida spp. The Clinical Laboratory Standards Institute (CLSI) reference broth microdilution method was performed to test 5,720 clinical isolates of six different Candida species. Species-specific interpretative criteria by CLSI breakpoints or epidemiological cutoff values were applied. Essential agreement was 100% within two doubling dilutions for all species and comparisons. The categorical agreement of rezafungin using anidulafungin against all Candida spp. was 97.6% (2.9% very major errors [VMEs], 0.2% major errors [MEs], and 2.2% minor errors [miEs]); for caspofungin, it was 99.6% (11.4% VME, 0.09% ME, and 0.19% miE); and for micafungin, it was 99.6% (14.3% VME, 0.15% ME, and 0.17% miE). There were species-specific differences that led to unacceptably high VME for Candida dubliniensis with all agents and for Candida parapsilosis when caspofungin or micafungin but not anidulafungin was used as the comparator. Genetic analysis showed rezafungin nonsusceptibility correlated well with FKS hotspot mutations. The best-performing surrogate was anidulafungin, which can be used to predict rezafungin susceptible or nonsusceptible in Candida albicans, Candida glabrata, Candida parapsilosis, Candida tropicalis, and Candida krusei with low error rates and ≥90% essential and categorical agreement. Micafungin or caspofungin can also be used as a surrogate marker for predicting rezafungin susceptible or nonsusceptible in C. albicans , C. glabrata , C. tropicalis , and C. krusei . No surrogate performs appropriately to determine rezafungin susceptibility for C. dubliniensis .
- 19 February 2025
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 63 (2) , e0112924
Open AccessAnidulafungin is a useful surrogate marker for predicting in vitro susceptibility to rezafungin among five Candida species using CLSI methods and interpretive criteria
This study addresses the use of other echinocandins as surrogate markers to predict the susceptibility of rezafungin against the six most common Candida spp. The Clinical Laboratory Standards Institute (CLSI) reference broth microdilution method was performed to test 5,720 clinical isolates of six different Candida species. Species-specific interpretative criteria by CLSI breakpoints or epidemiological cutoff values were applied. Essential agreement was 100% within two doubling dilutions for all species and comparisons. The categorical agreement of rezafungin using anidulafungin against all Candida spp. was 97.6% (2.9% very major errors [VMEs], 0.2% major errors [MEs], and 2.2% minor errors [miEs]); for caspofungin, it was 99.6% (11.4% VME, 0.09% ME, and 0.19% miE); and for micafungin, it was 99.6% (14.3% VME, 0.15% ME, and 0.17% miE). There were species-specific differences that led to unacceptably high VME for Candida dubliniensis with all agents and for Candida parapsilosis when caspofungin or micafungin but not anidulafungin was used as the comparator. Genetic analysis showed rezafungin nonsusceptibility correlated well with FKS hotspot mutations. The best-performing surrogate was anidulafungin, which can be used to predict rezafungin susceptible or nonsusceptible in Candida albicans, Candida glabrata, Candida parapsilosis, Candida tropicalis, and Candida krusei with low error rates and ≥90% essential and categorical agreement. Micafungin or caspofungin can also be used as a surrogate marker for predicting rezafungin susceptible or nonsusceptible in C. albicans , C. glabrata , C. tropicalis , and C. krusei . No surrogate performs appropriately to determine rezafungin susceptibility for C. dubliniensis .
- Open Access
- 8 October 2024
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 68 (10) , e0057024
Recent increase in Candida auris frequency in the SENTRY surveillance program: antifungal activity and genotypic characterization
We observed an increase in the frequency of Candida auris among invasive candidiasis isolates in the 2022 SENTRY Antifungal Surveillance Program compared to prior years: ≤0.1% before 2018, 0.4%–0.6% from 2018 to 2021, and 1.6% in 2022. C. auris isolates were collected in seven countries, but 28 (35.9%) isolates were recovered in the USA (five states; more common in New York, Texas, and New Jersey) and 26 (33.3%) in Panama. Greece and Turkey had 12 and 9 isolates, respectively. Overall, 82.1% of the isolates were resistant to fluconazole; 17.9% were resistant to amphotericin B; and 1.3% were resistant to caspofungin, anidulafungin, or micafungin (Centers for Disease Control and Prevention tentative resistance breakpoints). Rezafungin inhibited 96.2% of the isolates (Clinical and Laboratory Standards Institute susceptibility breakpoint). Pandrug resistance was not observed, but 17.9% of the isolates were resistant to fluconazole and amphotericin B. South Asian (Clade I) isolates were most common ( n = 40, 51.3%); of these, 97.5% were resistant to fluconazole and 30.0% were resistant to amphotericin B. Thirty (38.5%) isolates belonged to the South American region (Clade IV), and 56.7% of those were resistant to fluconazole and 6.7% to amphotericin B. Seven isolates belonged to the South African Clade III and one to East Asian Clade II. Erg11 (Y132F, K143R, and F126L) and MRR1 (N647T) alterations were detected. One isolate that was resistant to all echinocandins carried an FKS R1354G alteration. Two isolates displayed elevated rezafungin minimum inhibitory concentration (MIC) values but low MIC values against other echinocandins and no FKS alterations. As C. auris is spreading globally, monitoring this species is prudent.
- 8 October 2024
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 68 (10) , e0057024
Open AccessRecent increase in Candida auris frequency in the SENTRY surveillance program: antifungal activity and genotypic characterization
We observed an increase in the frequency of Candida auris among invasive candidiasis isolates in the 2022 SENTRY Antifungal Surveillance Program compared to prior years: ≤0.1% before 2018, 0.4%–0.6% from 2018 to 2021, and 1.6% in 2022. C. auris isolates were collected in seven countries, but 28 (35.9%) isolates were recovered in the USA (five states; more common in New York, Texas, and New Jersey) and 26 (33.3%) in Panama. Greece and Turkey had 12 and 9 isolates, respectively. Overall, 82.1% of the isolates were resistant to fluconazole; 17.9% were resistant to amphotericin B; and 1.3% were resistant to caspofungin, anidulafungin, or micafungin (Centers for Disease Control and Prevention tentative resistance breakpoints). Rezafungin inhibited 96.2% of the isolates (Clinical and Laboratory Standards Institute susceptibility breakpoint). Pandrug resistance was not observed, but 17.9% of the isolates were resistant to fluconazole and amphotericin B. South Asian (Clade I) isolates were most common ( n = 40, 51.3%); of these, 97.5% were resistant to fluconazole and 30.0% were resistant to amphotericin B. Thirty (38.5%) isolates belonged to the South American region (Clade IV), and 56.7% of those were resistant to fluconazole and 6.7% to amphotericin B. Seven isolates belonged to the South African Clade III and one to East Asian Clade II. Erg11 (Y132F, K143R, and F126L) and MRR1 (N647T) alterations were detected. One isolate that was resistant to all echinocandins carried an FKS R1354G alteration. Two isolates displayed elevated rezafungin minimum inhibitory concentration (MIC) values but low MIC values against other echinocandins and no FKS alterations. As C. auris is spreading globally, monitoring this species is prudent.
- Open Access
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
1947. Activity of Rezafungin against Echinocandin–Non-wild type C. glabrata Clinical Isolates from the Rezafungin Surveillance Program (2014–2021)
A total of 1045 CGLA collected (1/patient) in 2014–2021 from 58 medical centers located in North America (NA; n=459; 20 centers), Europe (EU; n=396; 23 centers), Asia-Pacific (AP; n=130; 10 centers), and Latin America (LA, n=60; 5 centers) were identified by MALDI-TOF and/or sequencing and tested by CLSI broth microdilution. CLSI breakpoints (BP) and epidemiological cut-off values were applied. ECH NWT isolates were submitted to FKS analysis by whole genome sequencing. RZF showed similar activity to other ECHs against CGLA (Table), inhibiting 98.5% at ≤0.5 mg/L. Anidulafungin (ANF), caspofungin (CSF), and micafungin (MCF) susceptibility (S) rates were 96.2%, 97.5%, and 97.3%, respectively. ECH-NWT CGLA were detected in 42 isolates (4.0% overall): NA showed the highest rate of ECH NWT isolates (29; 6.3%), followed by EU (10; 2.5%), AP (2; 1.5%), and LA (1; 1.7%). The RZF S rate was 61.9% of ECH-NWT CGLA, while the S rate to ANF, CSF, and MCF was 21.4%, 40.5%, and 33.3%, respectively. Alteration in FKS genes were observed in 31 CGLA (73.8% of ECH NWT; 3.0% overall). RZF was active against >50% of these isolates. RFZ was also active against >90% of ECH-NWT CGLA carrying wildtype FKS genes. Equivalent activity was noted to other ECHs against ECH-NWT isolates. However, ECHs were 4 to 8-fold more active against ECH-NWT CGLA that did not display alterations in FKS genes than those with FKS alterations. FKS2 hot spot(HS)-1 alterations were observed in 22 isolates (12 displayed S663F), while FKS1-HS1 alterations were noted in 9 isolates (7 displayed S629P). FLC-R was observed in 6.9% of CGLA overall and 16.7% of the ECH-NWT isolates. RZF demonstrated potent in vitro activity against CGLA and remained active against most isolates of CGLA displaying an ECH-NWT phenotype with or without FKS alterations. Cecilia G. Carvalhaes, MD, PhD, AbbVie: Grant/Research Support|bioMerieux: Grant/Research Support|Cipla: Grant/Research Support|CorMedix: Grant/Research Support|Melinta: Grant/Research Support|Pfizer: Grant/Research Support Paul Rhomberg, BS, MT(ASCP), bioMerieux: Grant/Research Support|Melinta: Grant/Research Support|Pfizer: Grant/Research Support Abby Klauer, BS, Melinta: Grant/Research Support Lalitagauri M. Deshpande, PhD, Melinta: Grant/Research Support|Paratek: Grant/Research Support Mariana Castanheira, PhD, AbbVie: Grant/Research Support|Basilea: Grant/Research Support|bioMerieux: Grant/Research Support|Cipla: Grant/Research Support|CorMedix: Grant/Research Support|Entasis: Grant/Research Support|Melinta: Grant/Research Support|Paratek: Grant/Research Support|Pfizer: Grant/Research Support|Shionogi: Grant/Research Support
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
Open Access1947. Activity of Rezafungin against Echinocandin–Non-wild type C. glabrata Clinical Isolates from the Rezafungin Surveillance Program (2014–2021)
A total of 1045 CGLA collected (1/patient) in 2014–2021 from 58 medical centers located in North America (NA; n=459; 20 centers), Europe (EU; n=396; 23 centers), Asia-Pacific (AP; n=130; 10 centers), and Latin America (LA, n=60; 5 centers) were identified by MALDI-TOF and/or sequencing and tested by CLSI broth microdilution. CLSI breakpoints (BP) and epidemiological cut-off values were applied. ECH NWT isolates were submitted to FKS analysis by whole genome sequencing. RZF showed similar activity to other ECHs against CGLA (Table), inhibiting 98.5% at ≤0.5 mg/L. Anidulafungin (ANF), caspofungin (CSF), and micafungin (MCF) susceptibility (S) rates were 96.2%, 97.5%, and 97.3%, respectively. ECH-NWT CGLA were detected in 42 isolates (4.0% overall): NA showed the highest rate of ECH NWT isolates (29; 6.3%), followed by EU (10; 2.5%), AP (2; 1.5%), and LA (1; 1.7%). The RZF S rate was 61.9% of ECH-NWT CGLA, while the S rate to ANF, CSF, and MCF was 21.4%, 40.5%, and 33.3%, respectively. Alteration in FKS genes were observed in 31 CGLA (73.8% of ECH NWT; 3.0% overall). RZF was active against >50% of these isolates. RFZ was also active against >90% of ECH-NWT CGLA carrying wildtype FKS genes. Equivalent activity was noted to other ECHs against ECH-NWT isolates. However, ECHs were 4 to 8-fold more active against ECH-NWT CGLA that did not display alterations in FKS genes than those with FKS alterations. FKS2 hot spot(HS)-1 alterations were observed in 22 isolates (12 displayed S663F), while FKS1-HS1 alterations were noted in 9 isolates (7 displayed S629P). FLC-R was observed in 6.9% of CGLA overall and 16.7% of the ECH-NWT isolates. RZF demonstrated potent in vitro activity against CGLA and remained active against most isolates of CGLA displaying an ECH-NWT phenotype with or without FKS alterations. Cecilia G. Carvalhaes, MD, PhD, AbbVie: Grant/Research Support|bioMerieux: Grant/Research Support|Cipla: Grant/Research Support|CorMedix: Grant/Research Support|Melinta: Grant/Research Support|Pfizer: Grant/Research Support Paul Rhomberg, BS, MT(ASCP), bioMerieux: Grant/Research Support|Melinta: Grant/Research Support|Pfizer: Grant/Research Support Abby Klauer, BS, Melinta: Grant/Research Support Lalitagauri M. Deshpande, PhD, Melinta: Grant/Research Support|Paratek: Grant/Research Support Mariana Castanheira, PhD, AbbVie: Grant/Research Support|Basilea: Grant/Research Support|bioMerieux: Grant/Research Support|Cipla: Grant/Research Support|CorMedix: Grant/Research Support|Entasis: Grant/Research Support|Melinta: Grant/Research Support|Paratek: Grant/Research Support|Pfizer: Grant/Research Support|Shionogi: Grant/Research Support
- Open Access
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
2139. High Rates of Non-Susceptibility to Common Oral Antibiotics Among Streptococcus pneumoniae Clinical Isolates from the United States (2019-2021)
1,038 SPN from 31 USA centers (2019-2021) were tested by CLSI broth microdilution. Isolates were from CABP (933), bloodstream infection (72), or nosocomial pneumonia (33). A selection of 119 SPN with DOX MIC of 0.25 - >8 mg/L were subjected to genome sequencing for screening of acquired TET-R genes and target site mutations, and serotyping (ST). Most SPN isolates were susceptible (S) to OMC (99.8%; FDA), levofloxacin (LEV, 99.7%; CLSI) and tigecycline (TIG; 98.4%; FDA). Other agents had limited activity overall (penicillin 63.5%; or DOX 80.2%; or azithromycin 54.3%) with decreased S against isolates from certain US regions (Table). Only OMC (100% S), LEV (96.8% S) and TIG (96.7% S) were active against TET-NS (MIC, ≥2 mg/L) SPN. Cefpodoxime (70.5% S) and amoxicillin-clavulanate (82.0% S) had suboptimal activity against this R subset and other agent had S ≤36.1%. Isolates from the Pacific region tended to be more S than those from other regions. All TET-NS and 1 TET-S (MIC, 1 mg/L) isolates carried tet(M), and TET-NS had low S to DOX (6.6% S) and azithromycin (3.3% S). TET target site mutations were not observed. SPN belonged to 21 ST; 22F and 35B were the most common among TET-S SPN, whereas 15A, 19A, 09N, and 23A were common among TET-NS SPN. Options recommended for the empiric treatment of outpatients with CABP show low S against SPN from the US, except against isolates from the Pacific region. Tet(M) remains the dominant R mechanism, which did not affect OMC activity but significantly altered DOX activity. These data suggest that OMC represents a potential empiric option for treating pneumonia caused by SPN in the USA, including against isolates carrying tet(M). Lalitagauri M. Deshpande, PhD, Melinta: Grant/Research Support|Paratek: Grant/Research Support Michael D. Huband, BS, BARDA: This study has been funded in part by BARDA under Contract No. 75A50120C00001.|Entasis: Grant/Research Support|Paratek: Grant/Research Support|Pfizer: Grant/Research Support Sarah Charbon, MHS, MLS(ASCP)CM, Paratek: Grant/Research Support Mariana Castanheira, PhD, AbbVie: Grant/Research Support|Basilea: Grant/Research Support|bioMerieux: Grant/Research Support|Cipla: Grant/Research Support|CorMedix: Grant/Research Support|Entasis: Grant/Research Support|Melinta: Grant/Research Support|Paratek: Grant/Research Support|Pfizer: Grant/Research Support|Shionogi: Grant/Research Support Rodrigo E. Mendes, PhD, AbbVie: Grant/Research Support|Basilea: Grant/Research Support|Cipla: Grant/Research Support|Entasis: Grant/Research Support|GSK: Grant/Research Support|Paratek: Grant/Research Support|Pfizer: Grant/Research Support|Shionogi: Grant/Research Support
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
Open Access2139. High Rates of Non-Susceptibility to Common Oral Antibiotics Among Streptococcus pneumoniae Clinical Isolates from the United States (2019-2021)
1,038 SPN from 31 USA centers (2019-2021) were tested by CLSI broth microdilution. Isolates were from CABP (933), bloodstream infection (72), or nosocomial pneumonia (33). A selection of 119 SPN with DOX MIC of 0.25 - >8 mg/L were subjected to genome sequencing for screening of acquired TET-R genes and target site mutations, and serotyping (ST). Most SPN isolates were susceptible (S) to OMC (99.8%; FDA), levofloxacin (LEV, 99.7%; CLSI) and tigecycline (TIG; 98.4%; FDA). Other agents had limited activity overall (penicillin 63.5%; or DOX 80.2%; or azithromycin 54.3%) with decreased S against isolates from certain US regions (Table). Only OMC (100% S), LEV (96.8% S) and TIG (96.7% S) were active against TET-NS (MIC, ≥2 mg/L) SPN. Cefpodoxime (70.5% S) and amoxicillin-clavulanate (82.0% S) had suboptimal activity against this R subset and other agent had S ≤36.1%. Isolates from the Pacific region tended to be more S than those from other regions. All TET-NS and 1 TET-S (MIC, 1 mg/L) isolates carried tet(M), and TET-NS had low S to DOX (6.6% S) and azithromycin (3.3% S). TET target site mutations were not observed. SPN belonged to 21 ST; 22F and 35B were the most common among TET-S SPN, whereas 15A, 19A, 09N, and 23A were common among TET-NS SPN. Options recommended for the empiric treatment of outpatients with CABP show low S against SPN from the US, except against isolates from the Pacific region. Tet(M) remains the dominant R mechanism, which did not affect OMC activity but significantly altered DOX activity. These data suggest that OMC represents a potential empiric option for treating pneumonia caused by SPN in the USA, including against isolates carrying tet(M). Lalitagauri M. Deshpande, PhD, Melinta: Grant/Research Support|Paratek: Grant/Research Support Michael D. Huband, BS, BARDA: This study has been funded in part by BARDA under Contract No. 75A50120C00001.|Entasis: Grant/Research Support|Paratek: Grant/Research Support|Pfizer: Grant/Research Support Sarah Charbon, MHS, MLS(ASCP)CM, Paratek: Grant/Research Support Mariana Castanheira, PhD, AbbVie: Grant/Research Support|Basilea: Grant/Research Support|bioMerieux: Grant/Research Support|Cipla: Grant/Research Support|CorMedix: Grant/Research Support|Entasis: Grant/Research Support|Melinta: Grant/Research Support|Paratek: Grant/Research Support|Pfizer: Grant/Research Support|Shionogi: Grant/Research Support Rodrigo E. Mendes, PhD, AbbVie: Grant/Research Support|Basilea: Grant/Research Support|Cipla: Grant/Research Support|Entasis: Grant/Research Support|GSK: Grant/Research Support|Paratek: Grant/Research Support|Pfizer: Grant/Research Support|Shionogi: Grant/Research Support
- Open Access
- 30 September 2022
- Published by Oxford University Press (OUP) in JAC-Antimicrobial Resistance
- Vol. 4 (5) , dlac098
Prevalence of carbapenemase genes among carbapenem-nonsusceptible Enterobacterales collected in US hospitals in a five-year period and activity of ceftazidime/avibactam and comparator agents
To evaluate the prevalence of acquired β-lactamase genes and susceptibility profiles of carbapenem-nonsusceptible Enterobacterales (CNSE) clinical isolates collected in US hospitals during a 5-year period. Isolates were susceptibility tested by reference broth microdilution methods. Results were interpreted using CLSI breakpoints. Isolates displaying nonsusceptible MICs for imipenem or meropenem were categorized as CNSE. CNSE isolates were screened for β-lactamase-encoding genes using whole-genome sequencing. New genes were cloned, expressed in an Escherichia coli background and susceptibility tested. A total of 450 (1.3%) isolates were CNSE. Klebsiella pneumoniae serine carbapenemase (KPC) production was the most common resistance mechanism among CNSE isolates: 281/450 (62.4%) carried blaKPC, including three new variants. OXA-48-like and metallo-β-lactamase (MBL) encoding genes were detected among seven and 12 isolates, respectively. Among MBL genes, blaNDM-1 was the most common, but blaNDM-5, blaVIM-1 and blaIMP-27 were also identified. 169 (37.6% of the CNSE) isolates did not produce carbapenemases. Ceftazidime/avibactam was the most active agent (95.0% to 100.0% susceptible) against CNSE isolates from all carbapenemase groups except MBL-producing isolates. Ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam inhibited 100.0%, 97.6% and 92.3% of the non-carbapenemase CNSE isolates, respectively. Among the three new blaKPC variants, one conferred resistance to ceftazidime/avibactam and low meropenem MIC results while the other two had profiles similar to blaKPC-2 or blaKPC-3. A decline in carbapenemase production was noticed in US hospitals in the 5-year period analysed in this study. New β-lactam/β-lactamase inhibitor combinations tested had good activity against CNSE isolates.
- 30 September 2022
- Published by Oxford University Press (OUP) in JAC-Antimicrobial Resistance
- Vol. 4 (5) , dlac098
Open AccessPrevalence of carbapenemase genes among carbapenem-nonsusceptible Enterobacterales collected in US hospitals in a five-year period and activity of ceftazidime/avibactam and comparator agents
To evaluate the prevalence of acquired β-lactamase genes and susceptibility profiles of carbapenem-nonsusceptible Enterobacterales (CNSE) clinical isolates collected in US hospitals during a 5-year period. Isolates were susceptibility tested by reference broth microdilution methods. Results were interpreted using CLSI breakpoints. Isolates displaying nonsusceptible MICs for imipenem or meropenem were categorized as CNSE. CNSE isolates were screened for β-lactamase-encoding genes using whole-genome sequencing. New genes were cloned, expressed in an Escherichia coli background and susceptibility tested. A total of 450 (1.3%) isolates were CNSE. Klebsiella pneumoniae serine carbapenemase (KPC) production was the most common resistance mechanism among CNSE isolates: 281/450 (62.4%) carried blaKPC, including three new variants. OXA-48-like and metallo-β-lactamase (MBL) encoding genes were detected among seven and 12 isolates, respectively. Among MBL genes, blaNDM-1 was the most common, but blaNDM-5, blaVIM-1 and blaIMP-27 were also identified. 169 (37.6% of the CNSE) isolates did not produce carbapenemases. Ceftazidime/avibactam was the most active agent (95.0% to 100.0% susceptible) against CNSE isolates from all carbapenemase groups except MBL-producing isolates. Ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam inhibited 100.0%, 97.6% and 92.3% of the non-carbapenemase CNSE isolates, respectively. Among the three new blaKPC variants, one conferred resistance to ceftazidime/avibactam and low meropenem MIC results while the other two had profiles similar to blaKPC-2 or blaKPC-3. A decline in carbapenemase production was noticed in US hospitals in the 5-year period analysed in this study. New β-lactam/β-lactamase inhibitor combinations tested had good activity against CNSE isolates.
- Open Access
- 30 September 2022
- Published by Oxford University Press (OUP) in JAC-Antimicrobial Resistance
- Vol. 4 (5) , dlac097
Activity of meropenem/vaborbactam and comparators against non-carbapenemase-producing carbapenem-resistant Enterobacterales isolates from Europe
Carbapenem-resistant Enterobacterales (CRE) isolates have disseminated worldwide. CREs usually produce a carbapenemase; however, some isolates are negative for known carbapenemases. In this study, we evaluated the activity of meropenem/vaborbactam and comparators against CREs without a carbapenemase (nonCP CREs) collected from European hospitals from 2016 to 2019. 23 043 Enterobacterales clinical isolates were collected in 41 hospitals located in 20 countries. Susceptibility (S) testing was performed using the broth microdilution method. CLSI/EUCAST (2021) interpretive criteria were used. 978 CREs were identified with MICs >2 mg/L to meropenem or imipenem. Whole-genome sequencing was performed on each CRE isolate. 125 isolates were negative for carbapenemase genes, including blaKPC, blaNDM, blaIMP, blaVIM and blaOXA-48-like. NonCP CRE isolates were analysed for the presence of other β-lactamases, multilocus sequence types (ST) and mutations in outer membrane protein (OMP) sequences. Most nonCP CRE were Klebsiella pneumoniae (KPN; n = 97/125). 84.0% of nonCP CRE (n = 105) were from Poland, including 88 KPN. The most common β-lactamase was blaCTX-M-15 in 92/125 isolates. OMP disruptions or alterations were noted among 76 KPN. Among KPN isolates that had MLST typing, 30 belonged to ST11, 18 to ST152 and 17 to ST147, while 13 other STs were observed. Susceptibility to meropenem/vaborbactam was 96.0/97.6% (CLSI/EUCAST) while meropenem was 2.4/8.0%S. Meropenem/vaborbactam had potent in vitro activity against CRE isolates that lacked known carbapenemases. Resistance mechanisms observed among nonCP CREs included acquired β-lactamases and OMP alterations. These results indicate that meropenem/vaborbactam may be a useful treatment for infections caused by nonCP CREs.
- 30 September 2022
- Published by Oxford University Press (OUP) in JAC-Antimicrobial Resistance
- Vol. 4 (5) , dlac097
Open AccessActivity of meropenem/vaborbactam and comparators against non-carbapenemase-producing carbapenem-resistant Enterobacterales isolates from Europe
Carbapenem-resistant Enterobacterales (CRE) isolates have disseminated worldwide. CREs usually produce a carbapenemase; however, some isolates are negative for known carbapenemases. In this study, we evaluated the activity of meropenem/vaborbactam and comparators against CREs without a carbapenemase (nonCP CREs) collected from European hospitals from 2016 to 2019. 23 043 Enterobacterales clinical isolates were collected in 41 hospitals located in 20 countries. Susceptibility (S) testing was performed using the broth microdilution method. CLSI/EUCAST (2021) interpretive criteria were used. 978 CREs were identified with MICs >2 mg/L to meropenem or imipenem. Whole-genome sequencing was performed on each CRE isolate. 125 isolates were negative for carbapenemase genes, including blaKPC, blaNDM, blaIMP, blaVIM and blaOXA-48-like. NonCP CRE isolates were analysed for the presence of other β-lactamases, multilocus sequence types (ST) and mutations in outer membrane protein (OMP) sequences. Most nonCP CRE were Klebsiella pneumoniae (KPN; n = 97/125). 84.0% of nonCP CRE (n = 105) were from Poland, including 88 KPN. The most common β-lactamase was blaCTX-M-15 in 92/125 isolates. OMP disruptions or alterations were noted among 76 KPN. Among KPN isolates that had MLST typing, 30 belonged to ST11, 18 to ST152 and 17 to ST147, while 13 other STs were observed. Susceptibility to meropenem/vaborbactam was 96.0/97.6% (CLSI/EUCAST) while meropenem was 2.4/8.0%S. Meropenem/vaborbactam had potent in vitro activity against CRE isolates that lacked known carbapenemases. Resistance mechanisms observed among nonCP CREs included acquired β-lactamases and OMP alterations. These results indicate that meropenem/vaborbactam may be a useful treatment for infections caused by nonCP CREs.
- Open Access
- 13 May 2022
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 29, 371-377
Azole resistance in Candida glabrata clinical isolates from global surveillance is associated with efflux overexpression
- 13 May 2022
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 29, 371-377
Open AccessAzole resistance in Candida glabrata clinical isolates from global surveillance is associated with efflux overexpression